Remdesivir News and Research

RSS

Emory researchers identify key immune cell type that drives the transition from early to late COVID-19

Determining how SARS-CoV-2, the virus causing COVID-19, moves from an early stage of infection, when patients are largely asymptomatic, into a later stage when people may experience life-threatening inflammation in the lungs, is a critical step in understanding how to target and treat the disease more efficiently.

14 Jun 2022

Study investigates SARS-CoV-2 escape from nirmatrelvir

Researchers assessed SARS-CoV-2 Alpha, Delta, and Omicron variants’ resistance to nirmatrelvir, a protease inhibitor of SARS-CoV-2.

10 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Researchers investigated whether COVID-19 vaccination effectively protected adolescents in the United States from multisystem inflammatory syndrome (MIS).

2 Jun 2022

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Researchers hypothesized that the emergence of resistant SARS-CoV-2 variants can be anticipated by identifying possible escape mutations already present in the existing SARS-CoV-2 populations.

1 Jun 2022

Researchers evaluate atovaquone as a COVID-19 treatment

Researchers evaluated a drug, atovaquone, for COVID-19 treatment.

30 May 2022

Study explores the substrate selectivity of the SARS-CoV-2 replicase

Researchers explored factors affecting substrate selection by the SARS-CoV-2 replicase.

24 May 2022

Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study

A new paper presents the results of a mouse study using the repurposed antibacterial drug clofoctol against this virus.

23 May 2022

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

A new study has revealed that ATV006, which is a 5′-hydroxyl-isobutyryl prodrug, possesses extraordinary oral pharmaco-kinetic (PK) profiles in rats and cynomolgus monkeys and exhibited significant antiviral activity against ancestral SARS-COV-2 strain as well as VOCs.

20 May 2022

Early impact of SARS-CoV-2 on human lungs

In a new study, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on human lung cells.

16 May 2022

CDC study of pregnant women hospitalized with COVID in 2021 found 93% not vaccinated

In a recent study posted to the Research Square* preprint server, researchers assessed the characteristics and treatment of coronavirus disease 2019 (COVID-19) in pregnant women.

12 May 2022

Research looks at potential of pantethine against SARS-CoV-2

In a recent study posted to the Research Square preprint server, researchers assessed the antiviral activity of pantethine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 May 2022

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

A recent study published in the journal The Lancet summarized the final results of the Solidarity trial which aimed at finding out which drugs were most effective at reducing the severity of the disease among hospitalized patients.

9 May 2022

Study investigates the cause of lymphopenia as seen in COVID-19 patients

Researchers explored the underlying mechanism resulting in thymic atrophy and subsequent lymphopenia in COVID-19 patients.

9 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

Remdesivir News and Research

Emory researchers identify key immune cell type that drives the transition from early to late COVID-19

Study investigates SARS-CoV-2 escape from nirmatrelvir

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Researchers evaluate atovaquone as a COVID-19 treatment

Study explores the substrate selectivity of the SARS-CoV-2 replicase

Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

Early impact of SARS-CoV-2 on human lungs

CDC study of pregnant women hospitalized with COVID in 2021 found 93% not vaccinated

Research looks at potential of pantethine against SARS-CoV-2

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

Study investigates the cause of lymphopenia as seen in COVID-19 patients

Marine bioactive compounds against SARS-CoV-2

SARS-CoV-2 develops partial resistance to the antiviral drug remdesivir in cell culture

Fourth dose of COVID-19 vaccine reduced death among hospitalized patients during Omicron wave in Israel

SARS-CoV-2 Mpro inhibitors built on rattlesnake venom scaffold

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News